Form 6-K DENISON MINES CORP. For: Apr 08

  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

Date: April 8, 2026

 

Commission File Number:  001-33414

 

Denison Mines Corp.

 

(Name of registrant)

 

1100-40 University Avenue

Toronto ON

M5J 1T1 Canada

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ¨     Form 40-F x

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

  

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	DENISON MINES CORP.
	/s/ Amanda Willett
Date: April 8, 2026	Amanda Willett
	Vice President Legal and Corporate Secretary

 

 

FORM 6-K EXHIBIT INDEX

 

Exhibit Number		Description
99.1		Management Information Circular
99.2		Notice of Meeting
99.3		Notice and Access Notification Letter
99.4		Form of Proxy
99.5		Form of Voting Instruction Form

 

 

ATTACHMENTS / EXHIBITS

EXHIBIT 99.1

EXHIBIT 99.2

EXHIBIT 99.3

EXHIBIT 99.4

EXHIBIT 99.5

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Luvme Hair Recognized as America’s #1 Human Hair Wig Brand
• Dimensional Fund Advisors Ltd. : Form 8.3 - AMG CRITICAL MATERIALS N.V. - Ordinary Shares
• Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA